BOONTON, N.J., Dec. 5, 2011 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) today announced that the Company terminated its amended and restated exclusive worldwide license agreement and ...
This multicenter, double blind with respect to placebo, randomized, repeat dose placebo controlled study will include an open label comparator arm of the Forsteo® injectable formulation. The primary ...
Oral Presentation and Poster Sessions to Highlight Positive Phase 2 Results of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Ashleigh Palmer, Unigene's Chief Executive Officer, ...
December 12, 2012 – Boonton, NJ – Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that the ...
The European Commission on Tuesday gave Eli Lilly & Co. approval to market its Forsteo osteoporosis treatment, which already is on sale in the U.S. The injectable medication, which is also known by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback